Matches in SemOpenAlex for { <https://semopenalex.org/work/W2263661221> ?p ?o ?g. }
Showing items 1 to 89 of
89
with 100 items per page.
- W2263661221 endingPage "1534" @default.
- W2263661221 startingPage "1529" @default.
- W2263661221 abstract "A phase II study of detorubicin, the semisynthetic 14-diethoxyacetoxy ester of daunorubicin, was conducted in 42 patients with metastatic melanoma. The drug was administered in a dose range of 120 to 180 mg/m2 and repeated at 3-week intervals. One clinical complete remission (soft tissue) and seven partial responses (three visceral and four soft tissue) were observed among the 22 patients who had undergone no prior chemotherapy, a complete and partial response rate of 36%. The duration of response varied from 2 to 27 months with a median of 10 months. There were also four (19%) minor responses (one visceral and three soft tissue). In contrast, among the 20 patients who had undergone prior chemotherapy treatment, only three patients showed a minor response. General toxicities were acceptable and were similar to those of Adriamycin (Adria Laboratories, Columbus, Ohio). Cardiac toxicity was evaluated by cardiac biopsy and radionuclide scan. Cardiac biopsy changes were identical to those observed with Adriamycin and were progressive with cumulative dose. One patient had a high-grade biopsy at a cumulative detorubicin dose of 1,420 mg/m2. Similarly, a trend of decreasing ejection fraction with cumulative dose was noted. Only one patient developed congestive heart failure at a cumulative dose of 1,290 mg/m2, that was well compensated with digoxin and diuretics. In contrast to Adriamycin, detorubicin has shown activity in previously untreated patients with metastatic melanoma." @default.
- W2263661221 created "2016-06-24" @default.
- W2263661221 creator A5046099119 @default.
- W2263661221 creator A5071770443 @default.
- W2263661221 creator A5073906112 @default.
- W2263661221 date "1985-11-01" @default.
- W2263661221 modified "2023-10-13" @default.
- W2263661221 title "Detorubicin--an active anthracycline in untreated metastatic melanoma." @default.
- W2263661221 cites W2007455730 @default.
- W2263661221 cites W2033339447 @default.
- W2263661221 cites W2064722407 @default.
- W2263661221 cites W2078530112 @default.
- W2263661221 cites W2084803292 @default.
- W2263661221 cites W2085396549 @default.
- W2263661221 cites W2220950919 @default.
- W2263661221 cites W2318955384 @default.
- W2263661221 cites W2343128466 @default.
- W2263661221 cites W2405304871 @default.
- W2263661221 cites W2411478214 @default.
- W2263661221 cites W2412826254 @default.
- W2263661221 cites W2413802674 @default.
- W2263661221 cites W2416401624 @default.
- W2263661221 cites W28958373 @default.
- W2263661221 doi "https://doi.org/10.1200/jco.1985.3.11.1529" @default.
- W2263661221 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/4056844" @default.
- W2263661221 hasPublicationYear "1985" @default.
- W2263661221 type Work @default.
- W2263661221 sameAs 2263661221 @default.
- W2263661221 citedByCount "9" @default.
- W2263661221 crossrefType "journal-article" @default.
- W2263661221 hasAuthorship W2263661221A5046099119 @default.
- W2263661221 hasAuthorship W2263661221A5071770443 @default.
- W2263661221 hasAuthorship W2263661221A5073906112 @default.
- W2263661221 hasConcept C121608353 @default.
- W2263661221 hasConcept C126322002 @default.
- W2263661221 hasConcept C141071460 @default.
- W2263661221 hasConcept C151032500 @default.
- W2263661221 hasConcept C2775934546 @default.
- W2263661221 hasConcept C2776694085 @default.
- W2263661221 hasConcept C2776802502 @default.
- W2263661221 hasConcept C2777658100 @default.
- W2263661221 hasConcept C2778198053 @default.
- W2263661221 hasConcept C2778233292 @default.
- W2263661221 hasConcept C29730261 @default.
- W2263661221 hasConcept C2989005 @default.
- W2263661221 hasConcept C502942594 @default.
- W2263661221 hasConcept C530470458 @default.
- W2263661221 hasConcept C71924100 @default.
- W2263661221 hasConcept C78085059 @default.
- W2263661221 hasConcept C90924648 @default.
- W2263661221 hasConceptScore W2263661221C121608353 @default.
- W2263661221 hasConceptScore W2263661221C126322002 @default.
- W2263661221 hasConceptScore W2263661221C141071460 @default.
- W2263661221 hasConceptScore W2263661221C151032500 @default.
- W2263661221 hasConceptScore W2263661221C2775934546 @default.
- W2263661221 hasConceptScore W2263661221C2776694085 @default.
- W2263661221 hasConceptScore W2263661221C2776802502 @default.
- W2263661221 hasConceptScore W2263661221C2777658100 @default.
- W2263661221 hasConceptScore W2263661221C2778198053 @default.
- W2263661221 hasConceptScore W2263661221C2778233292 @default.
- W2263661221 hasConceptScore W2263661221C29730261 @default.
- W2263661221 hasConceptScore W2263661221C2989005 @default.
- W2263661221 hasConceptScore W2263661221C502942594 @default.
- W2263661221 hasConceptScore W2263661221C530470458 @default.
- W2263661221 hasConceptScore W2263661221C71924100 @default.
- W2263661221 hasConceptScore W2263661221C78085059 @default.
- W2263661221 hasConceptScore W2263661221C90924648 @default.
- W2263661221 hasIssue "11" @default.
- W2263661221 hasLocation W22636612211 @default.
- W2263661221 hasLocation W22636612212 @default.
- W2263661221 hasOpenAccess W2263661221 @default.
- W2263661221 hasPrimaryLocation W22636612211 @default.
- W2263661221 hasRelatedWork W1992099483 @default.
- W2263661221 hasRelatedWork W2053291556 @default.
- W2263661221 hasRelatedWork W2396926985 @default.
- W2263661221 hasRelatedWork W2420051576 @default.
- W2263661221 hasRelatedWork W2569855433 @default.
- W2263661221 hasRelatedWork W2730846812 @default.
- W2263661221 hasRelatedWork W4316041250 @default.
- W2263661221 hasRelatedWork W4323066430 @default.
- W2263661221 hasRelatedWork W95894433 @default.
- W2263661221 hasRelatedWork W2157841994 @default.
- W2263661221 hasVolume "3" @default.
- W2263661221 isParatext "false" @default.
- W2263661221 isRetracted "false" @default.
- W2263661221 magId "2263661221" @default.
- W2263661221 workType "article" @default.